Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 29;14(9):1910.
doi: 10.3390/v14091910.

Double and Triple Combinations of Broadly Neutralizing Antibodies Provide Efficient Neutralization of All HIV-1 Strains from the Global Panel

Affiliations

Double and Triple Combinations of Broadly Neutralizing Antibodies Provide Efficient Neutralization of All HIV-1 Strains from the Global Panel

Evgeniya A Kochina et al. Viruses. .

Abstract

The use of broadly neutralizing antibodies (bNAbs) is a promising approach to HIV-1 treatment. In this work, we evaluate the neutralizing activity of the following HIV-1 bNAbs: VCR07-523, N6, PGDM1400, CAP256-VRC26.25, 10-1074, PGT128, 10E8, and DH511.11P, which are directed to different Env surface epitopes. We used the global panel of HIV-1 pseudoviruses to analyze the bNAbs' potency and chose the most potent ones. To achieve maximum neutralization breadth and minimum IC50 concentration, the most effective antibodies were tested in double and triple combinations. Among the doubles, the combinations of N6+PGDM1400 and N6+PGT128 with IC50 ≤ 0.3 µg/mL proved to be the most effective. The most effective triple combination was N6+PGDM1400+PGT128. Our data demonstrate that this combination neutralizes pseudoviruses of the global HIV-1 panel with IC50 ≤ 0.11 µg/mL and IC80 ≤ 0.25 µg/mL.

Keywords: 10-1074; 10E8; CAP256-VRC26.25; DH511.11P; Env; HIV-1; HIV-1 global panel; N6; PGDM1400; PGT128; VCR07-523; broadly neutralizing antibodies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure A1
Figure A1
Schematic representation of expression cassettes encoding the heavy and light chains of antibodies: CMV, cytomegalovirus promoter; Kozak, Kozak sequence; HGH signal LC/HC, signal peptide; VH/VL, variable domain of heavy/light chain; CH/CL, constant domain of heavy/light chain; PolyA, SV40 polyadenylation signal.
Figure A2
Figure A2
Pseudoviruses neutralization curves for bNAbs (AH) (n = 2, ±SEM, on the Y-scale, 100% means no neutralization and 0%—complete neutralization).
Figure A2
Figure A2
Pseudoviruses neutralization curves for bNAbs (AH) (n = 2, ±SEM, on the Y-scale, 100% means no neutralization and 0%—complete neutralization).
Figure A2
Figure A2
Pseudoviruses neutralization curves for bNAbs (AH) (n = 2, ±SEM, on the Y-scale, 100% means no neutralization and 0%—complete neutralization).
Figure A2
Figure A2
Pseudoviruses neutralization curves for bNAbs (AH) (n = 2, ±SEM, on the Y-scale, 100% means no neutralization and 0%—complete neutralization).
Figure A2
Figure A2
Pseudoviruses neutralization curves for bNAbs (AH) (n = 2, ±SEM, on the Y-scale, 100% means no neutralization and 0%—complete neutralization).
Figure 1
Figure 1
Schematic representation of glycoprotein Env homotrimer on the viral membrane. Each monomer consists of noncovalently bound gp120 and gp41 polyproteins. Epitopes for bNAbs are depicted in different colors. bNAbs used in this work are listed in frames.
Figure 2
Figure 2
Antibody concentration (ELISA, total human IgG) (n = 3, ±SEM).
Figure 3
Figure 3
Western blot analysis of broadly neutralizing antibodies under reducing conditions.
Figure 4
Figure 4
Pseudoviruses neutralization curves for bNAbs combinations (n = 2, ±SEM, on the Y-scale, 100% means no neutralization and 0%—complete neutralization).

Similar articles

Cited by

References

    1. UNAIDS AIDS Statistics. [(accessed on 25 April 2022)]. Available online: https://www.unaids.org/ru/resources/fact-sheet.
    1. WHO. [(accessed on 25 April 2022)]. Available online: https://www.who.int/news-room/fact-sheets/detail/hiv-drugresistance.
    1. Scheid J.F., Mouquet H., Feldhahn N., Seaman M.S., Velinzon K., Pietzsch J. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009;458:636–640. doi: 10.1038/nature07930. - DOI - PubMed
    1. Tiller T., Meffre E., Yurasov S., Tsuiji M., Nussenzweig M.C., Wardemann H. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods. 2008;329:112–124. doi: 10.1016/j.jim.2007.09.017. - DOI - PMC - PubMed
    1. Kepler T.B., Wiehe K. Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. Immunol. Rev. 2017;275:129–144. doi: 10.1111/imr.12513. - DOI - PMC - PubMed